Loading
journalsJournal
Leukemia
Leukemia is a Springer Nature haematology journal covering leukaemia, lymphoma and myeloma biology and clinical research, including the International Myeloma Working Group consensus papers.
Also called: Leukemia (Springer Nature)
Overview
Leukemia is a Springer Nature haematology journal, founded in 1987, appearing monthly and published on a hybrid access model. It covers leukaemia, lymphoma and myeloma biology and clinical research, publishing genomic and clonal-evolution studies of leukaemia, myeloma and MDS, phase 2 trials and long-term follow-up, and the International Myeloma Working Group and European LeukemiaNet consensus and response criteria. Its readers are haematologists and translational researchers in blood cancers who need the consensus definitions that trials are built on. Within OnCo it is linked from the Katayoun Rezvani biography, and it is where a reader would look for myeloma and leukaemia consensus papers and clonal-evolution studies.
Publisher
Springer Nature
Scope
haematology
Website
Access model
hybrid
Founded
1987
ISSN
0887-6924
Impact factor (2023)
12.8 · Clarivate Journal Citation Reports 2024 (2023 JIF)
rct2022138 citations
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
guideline2022changed practice3,151 citations
WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms
Every lymphoma diagnosis on this site refers to an entity in this classification or the parallel International Consensus Classification.
guideline2022changed practice3,281 citations
WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms
The names and definitions on a marrow report (for example MDS with biallelic TP53 inactivation, or AML myelodysplasia-related) come from this document or from the parallel International Consensus Classification.
review2020381 citations
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
One of the most cited reviews Europe PMC returns for BCMA in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
guideline2020changed practice1,100 citations
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia
Whether a patient is on track at three, six and twelve months, and when a change of drug or a transplant referral is warranted, is judged against these milestones.
review2010396 citations
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
One of the most cited reviews Europe PMC returns for JAK2 in Myeloproliferative neoplasms, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Biju George
Director, Christian Medical College, Vellore
Academic medicineHospital managementMedical education
Physician who serves as Director of Christian Medical College, Vellore, the not-for-profit teaching hospital and medical school in Tamil Nadu, India.
Christian Brandts
Director, UCT Frankfurt (Geschäftsführender Direktor)
Haematology and medical oncologyLeukaemiaCancer centre management
Haematologist-oncologist who is Managing Director of the University Cancer Center Frankfurt.
Jesús San Miguel
President, Internal Scientific Committee
Multiple myelomaHematologyMinimal residual disease
Hematologist who chairs the Cancer Center CUN internal scientific committee and is one of the most influential clinical investigators in multiple myeloma.
Katayoun Rezvani
Professor of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center
CAR-NK cell therapyCord blood-derived cell therapyAllogeneic immunotherapy
Created cord blood-derived CAR-NK cells, the first off-the-shelf CAR cell therapy to show remissions in lymphoma.
Thomas P. Loughran Jr.
Director, UVA Comprehensive Cancer Center
Cancer centre leadershipAcademic medicine
Director who leads the UVA Comprehensive Cancer Center in Charlottesville, Virginia's first NCI-designated comprehensive cancer centre.
Yuqin Song
Vice President
LymphomaHaematologic oncologyNovel agents in B-cell malignancies
Lymphoma specialist and Vice President of Peking University Cancer Hospital.
rctLeukemia 2022138 citations
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
guidelineLeukemia 2022changed practice3,151 citations
WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms
Every lymphoma diagnosis on this site refers to an entity in this classification or the parallel International Consensus Classification.
guidelineLeukemia 2022changed practice3,281 citations
WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms
The names and definitions on a marrow report (for example MDS with biallelic TP53 inactivation, or AML myelodysplasia-related) come from this document or from the parallel International Consensus Classification.
reviewLeukemia 2020381 citations
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
One of the most cited reviews Europe PMC returns for BCMA in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
guidelineLeukemia 2020changed practice1,100 citations
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia
Whether a patient is on track at three, six and twelve months, and when a change of drug or a transplant referral is warranted, is judged against these milestones.
reviewLeukemia 2010396 citations
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
One of the most cited reviews Europe PMC returns for JAK2 in Myeloproliferative neoplasms, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Similar pages
terms
people
key papers
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approachesEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemiaLong-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasmsWHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms